New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma

Hypertension (17.1% vs 8.7%) and venous thrombotic events (10.2% vs 6.2%) occurred more often with carfilzomib. Otherwise, the incidence of acute renal failure, cardiac failure, ischemic heart disease, and peripheral neuropathy occurred in a similar proportion of patients in both groups. The most common grade ≥3 special interest AE was hypertension (6.4% with carfilzomib). No other grade ≥3 special-interest event occurred in as many as 5% of patients.

“The safety is consistent with previous findings, and no new safety signals were observed for carfilzomib, lenalidomide, and dexamethasone after extended follow-up,” said Stewart.

---

References